Use of Virologic Assays in the Diagnosis and Management of Hepatitis C Virus Infection
Department of Virology, INSERM U635, Henri Mondor Hospital, University of Paris XII, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France. Clinics in Liver Disease
(Impact Factor: 3.66).
09/2005; 9(3):371-82, v. DOI: 10.1016/j.cld.2005.05.009
Virologic tests are invaluable in the management of HCV infection. They can be used to diagnose HCV infection, guide treatment decision, and assess the virologic response to therapy. Further work is necessary to better standardize the tests, to develop fully automated systems in molecular biology assays, and to define more clinically relevant thresholds on which to base universal recommendations for patient care. This, together with the development of new antiviral drugs and novel therapeutic approaches, should allow us to optimize the treatment of HCV infection.
Available from: Fuat Kurbanov
- "Regarding the NAT, different methods based on branched DNA (bDNA) and polymerase chain reaction (PCR) technology assays have been developed [Pawlotsky et al., 1999]. Real-time detection reverse-transcription (RT) PCR (RT-PCR) based assays have replaced endpoint PCR in the routine monitoring of HCV RNA level throughout the management of chronic hepatitis C patients [Chevaliez and Pawlotsky, 2005]. "
[Show abstract] [Hide abstract]
ABSTRACT: Accuracy for monitoring of the concentration of hepatitis C virus (HCV) RNA represents a major challenge throughout the management of patients with chronic hepatitis C. To investigate the genotype-independent efficiency and the accuracy of two real-time detection reverse transcription-polymerase chain reaction (RT-PCR) assays; the Cobas Ampliprep/Cobas TaqMan (CAP/CTM); and the Abbott RealTime HCV (ART), a total of 184 samples with different HCV subtypes were examined; 1b (n=58), 2a (n=39), 2b (n=26), 3a (n=20), and 4 (n=41). A robust linear correlation was observed between the two assays applied to genotypes 1b, 2a, 2b, and 3a [the correlation coefficient (R) ranged from 0.99 to 0.98], but not to genotype 4 specimens (R=0.78). A significant difference in measurements of HCV RNA using CAP/CTM and ART in serum samples with genotypes 1b and 4 was observed (0.72, -0.53 log IU/ml, P<0.0001, 0.01, respectively). A robust correlation was observed between the HCV core antigen and HCV RNA values by either of the HCV RNA quantitation assays applied to all genotypes with exception of genotype 4, for which R was higher with ART (R=0.95) than with CAP/CTM (R=0.80). The lower limit of detection of CAP/CTM and ART were 41.4 and 28.5 IU/ml using the WHO standards, respectively. In conclusion, two RT-PCR assays had a high efficiency and accuracy for quantitation of HCV RNA of genotypes 2a, 2b, and 3a, but the mean values of HCV RNA differed for genotype 1b and 4.
Journal of Medical Virology 11/2010; 82(11):1878-88. DOI:10.1002/jmv.21911 · 2.35 Impact Factor
Gastroenterología y Hepatología 10/2006; 29. DOI:10.1157/13097589 · 0.84 Impact Factor
Available from: Jia-Horng Kao
[Show abstract] [Hide abstract]
ABSTRACT: The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on the “APASL Consensus Statements and Management Algorithms for Hepatitis C Virus Infection” in December, 2010, in order to revise “Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection (J Gastroenterol Hepatol 22:615–633, 2007)”. The working party consisted of expert hepatologists from the Asian-Pacific region gathered at Makuhari, Chiba, Japan on 19 December 2010. New data were presented, discussed and debated to draft a revision. Participants of the consensus meeting assessed the quality of cited studies. Finalized recommendations are presented in this review.
Hepatology International 04/2012; 6(2). DOI:10.1007/s12072-012-9342-y · 1.78 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.